 Osteosarcoma
"Osteosarcoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)
| Descriptor ID |
D012516
|
| MeSH Number(s) |
C04.557.450.565.575.650 C04.557.450.795.620
|
| Concept/Terms |
Osteosarcoma- Osteosarcoma
- Osteosarcomas
- Osteosarcoma Tumor
- Osteosarcoma Tumors
- Tumor, Osteosarcoma
- Tumors, Osteosarcoma
- Sarcoma, Osteogenic
- Osteogenic Sarcomas
- Sarcomas, Osteogenic
- Osteogenic Sarcoma
|
Below are MeSH descriptors whose meaning is more general than "Osteosarcoma".
Below are MeSH descriptors whose meaning is more specific than "Osteosarcoma".
This graph shows the total number of publications written about "Osteosarcoma" by people in UAMS Profiles by year, and whether "Osteosarcoma" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2020 | 1 | 0 | 1 | | 2019 | 2 | 0 | 2 | | 2018 | 1 | 2 | 3 | | 2017 | 3 | 1 | 4 | | 2016 | 2 | 0 | 2 | | 2014 | 0 | 1 | 1 | | 2013 | 0 | 1 | 1 | | 2010 | 1 | 0 | 1 | | 2009 | 1 | 0 | 1 | | 2008 | 1 | 0 | 1 | | 2006 | 1 | 0 | 1 | | 2004 | 1 | 1 | 2 | | 2003 | 1 | 0 | 1 | | 1999 | 1 | 0 | 1 | | 1998 | 0 | 1 | 1 | | 1995 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Osteosarcoma" by people in Profiles over the past ten years.
-
Zhang Z, Ha SH, Moon YJ, Hussein UK, Song Y, Kim KM, Park SH, Park HS, Park BH, Ahn AR, Lee SA, Ahn SJ, Kim JR, Jang KY. Inhibition of SIRT6 potentiates the anti-tumor effect of doxorubicin through suppression of the DNA damage repair pathway in osteosarcoma. J Exp Clin Cancer Res. 2020 Nov 17; 39(1):247.
-
Zheng G, Richmond A, Liu C, Berrebi A, Pallavajjala A, Haley L, Stone RL, McCarthy E, Vang R, Xing D. Clinicopathologic Features and Genetic Alterations of a Primary Osteosarcoma of the Uterine Corpus. Int J Gynecol Pathol. 2019 Sep; 38(5):414-419.
-
Kim KM, Hussein UK, Park SH, Kang MA, Moon YJ, Zhang Z, Song Y, Park HS, Bae JS, Park BH, Ha SH, Moon WS, Kim JR, Jang KY. FAM83H is involved in stabilization of ß-catenin and progression of osteosarcomas. J Exp Clin Cancer Res. 2019 Jun 18; 38(1):267.
-
Park HJ, Bae JS, Kim KM, Moon YJ, Park SH, Ha SH, Hussein UK, Zhang Z, Park HS, Park BH, Moon WS, Kim JR, Jang KY. The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma. J Exp Clin Cancer Res. 2018 May 21; 37(1):107.
-
Parrales A, McDonald P, Ottomeyer M, Roy A, Shoenen FJ, Broward M, Bruns T, Thamm DH, Weir SJ, Neville KA, Iwakuma T, Fulbright JM. Comparative oncology approach to drug repurposing in osteosarcoma. PLoS One. 2018; 13(3):e0194224.
-
Nicholas RW. CORR Insights®: MRI Identification of the Osseous Extent of Pediatric Bone Sarcomas. Clin Orthop Relat Res. 2018 03; 476(3):565-567.
-
Sangoi AR, Kshirsagar M, Roma AA, Horvai AE, Chivukula M, Ellenson LH, Fadare O, Folkins AK, Garg K, Hanley K, Longacre TA, Haas J, McCluggage WG, McKenney JK, Nucci MR, Oliva E, Park KJ, Parkash V, Quick CM, Rabban JT, Rutgers JKL, Soslow R, Vang R, Yemelyanova A, Zaloudek C, Beck AH. Interobserver Reproducibility Among Gynecologic Pathologists in Diagnosing Heterologous Osteosarcomatous Component in Gynecologic Tract Carcinosarcomas. Int J Gynecol Pathol. 2017 Jul; 36(4):386-392.
-
Patel K, Kinnear D, Quintanilla NM, Hicks J, Castro E, Curry C, Dormans J, Ashton DJ, Hernandez JA, Wu H. Optimal Diagnostic Yield Achieved With On-site Pathology Evaluation of Fine-Needle Aspiration-Assisted Core Biopsies for Pediatric Osseous Lesions: A Single-Center Experience. Arch Pathol Lab Med. 2017 May; 141(5):678-683.
-
Leung JW, Makharashvili N, Agarwal P, Chiu LY, Pourpre R, Cammarata MB, Cannon JR, Sherker A, Durocher D, Brodbelt JS, Paull TT, Miller KM. ZMYM3 regulates BRCA1 localization at damaged chromatin to promote DNA repair. Genes Dev. 2017 02 01; 31(3):260-274.
-
Angulo P, Kaushik G, Subramaniam D, Dandawate P, Neville K, Chastain K, Anant S. Natural compounds targeting major cell signaling pathways: a novel paradigm for osteosarcoma therapy. J Hematol Oncol. 2017 01 07; 10(1):10.
-
Romano RC, Gardner JM, Shalin SC, Ram R, Govindarajan R, Montgomery CO, Gilley JH, Nicholas RW. High Relative Expression of Pannexin 3 (PANX3) in an Axillary Sweat Gland Carcinoma With Osteosarcomatous Transformation. Am J Dermatopathol. 2016 Nov; 38(11):846-851.
-
Stine KC, Wahl EC, Liu L, Skinner RA, VanderSchilden J, Bunn RC, Montgomery CO, Aronson J, Becton DL, Nicholas RW, Swearingen CJ, Suva LJ, Lumpkin CK. Nutlin-3 treatment spares cisplatin-induced inhibition of bone healing while maintaining osteosarcoma toxicity. J Orthop Res. 2016 10; 34(10):1716-1724.
-
Pérez-Campo FM, Sañudo C, Delgado-Calle J, Arozamena J, Zarrabeitia MT, Riancho JA. A Sclerostin super-producer cell line derived from the human cell line SaOS-2: a new tool for the study of the molecular mechanisms driving Sclerostin expression. Calcif Tissue Int. 2014 Aug; 95(2):194-9.
-
Coca-Pelaz A, Rodrigo JP, Triantafyllou A, Hunt JL, Fernández-Miranda JC, Strojan P, de Bree R, Rinaldo A, Takes RP, Ferlito A. Chondrosarcomas of the head and neck. Eur Arch Otorhinolaryngol. 2014 Oct; 271(10):2601-9.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|